AstraZeneca Plc expects revenue this year, excluding results from its Covid-19 vaccine Vaxzevria, to increase by a low twenties percentage, in line with earlier guidance. The forecast follows the publication of third quarter results on 12 November which showed total revenue of $9.9 billion, up by 50% from a year earlier. The results incorporate revenue from Alexion Pharmaceuticals Inc, a recent acquisition, as well as receipts from Vaxzevria.Total revenue for the nine month-period was $25.4 billion, up by 32%.
